BAX

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Baxter International Inc.

Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, it has been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.
CEO
Jose Almeida
Employees
2021
Headquarters

1 Baxter Pkwy
Deerfield, Illinois 60015-4625
Phone: 18479482000
www.baxter.com

News

FDA classifies Baxter’s hospital bed system recall as most serious
Nov 23, 2022 20:48pm

The U.S. health regulator on Wednesday classified the recall of hospital bed systems by Baxter International Inc, as the most serious type, on concerns it could lead to life-threatening injuries or death. Baxter initiated the recall of its WatchCare Incontinence Management System, which is used to discreetly alert an incontinent patient’s caregiver of involuntary urination […]


Source:National Post
Baxter recalls WatchCare devices over interference risk (NYSE:BAX)
Nov 23, 2022 18:11pm

The U.S. Food and Drug Administration ((FDA)) announced Wednesday that Baxter International (BAX) had recalled more than 8,500 WatchCare Incontinence Management Systems after finding…


Source:Seeking Alpha
Do you want to know where to find good stock? Take a look at Baxter International Inc.’s (NYSE:BAX) Sentiment Analysis
Nov 18, 2022 20:08pm

Currently, Baxter International Inc.’s (BAX) stock is trading at $54.89, marking a gain of 1.05% from last night’s close. At this price, the stock is -38.81% below its 52-week high of $89.70 and 10.15% above its 52-week low of $49.83. Based on the past 30-day period, the stock price is -5.42% below the high and […]


Source:US Post News
Ventricle Assist Devices (Vad) Market to Witness Huge Growth by Key Players: Xenios AG, Terumo Heart, Nikkiso, Baxter International, Jarvik Heart, St Jude Medical
Nov 16, 2022 06:47am

The Ventricle Assist Devices (Vad) research report studies primary and secondary research in order to analyze the data effectively. The market study further also draws attention to crucial industry factors such as global clients, potential customers, and sellers, which instigates


Source:OpenPR
Frost & Sullivan Institute recognizes Exemplary Companies winning the Enlightened Growth Leadership Awards for the Second time
Nov 11, 2022 07:08am


Source:Kwhen Finance
Rockwell to reacquire distribution rights for hemodialysis business from Baxter
Nov 09, 2022 11:31am

Rockwell Medical (RMTI) said it is reacquiring distribution rights to its hemodialysis concentrates products from Baxter (BAX) and agreed to terminate the exclusive distribution…


Source:Seeking Alpha
Baxter International Inc. (NYSE: BAX) Is Expected To Hit 73.00 USD!!
Oct 29, 2022 20:00pm

Baxter International Inc. (NYSE:BAX) shares, rose in value on Friday, 10/28/22, with the stock price up by 1.91% to the previous day’s close as strong demand from buyers drove the stock to $55.00. Actively observing the price movement in the last trading, the stock closed the session at $53.97, falling within a range of $53.60 … Baxter International Inc. (NYSE: BAX) Is Expected To Hit 73.00 USD!! Read More »


Source:Stocks Register
Baxter International PT Lowered to $64 at Citi
Oct 27, 2022 21:01pm

https://www.investing.com/news/pro/baxter-international-pt-lowered-to-64-at-citi-432SI-2924499


Source:Investing.com
Baxter Q3 Performance underwhelms Investors, FY22 Guidance Lags Consensus
Oct 27, 2022 16:47pm

Baxter International Inc (NYSE: BAX) posted Q3 revenue of $3.77 billion , which missed the consensus of $3.94 billion, up 17% on a reported basis, 23% on a constant currency basis, and rising slightly on an operational basis. Adjusted EPS of $0.82 came in line with the consensus and the management guidance of $0.79- $0.83. Renal Care, Clinical Nutrition, and Advanced Surgery delivered mid-single-digit growth. Medication Delivery … Full story available on Benzinga.com


Source:Benzinga
Recap: Baxter Intl Q3 Earnings
Oct 27, 2022 12:49pm

Baxter Intl (NYSE: BAX ) reported its Q3 earnings results on Thursday, October 27, 2022 at 07:15 AM. Here''s what investors need to know about the announcement. Earnings Baxter Intl reported in-line EPS of $0.82 versus an estimate of $0.82. Revenue … Full story available on Benzinga.com


Source:Benzinga
ROUNDUP: Baxter Sees Q4 Earnings Below Market; Cuts FY22 View, Now Sees Net Loss
Oct 27, 2022 12:40pm

DEERFIELD (dpa-AFX) - While announcing third-quarter results, medtech firm Baxter International Inc. (BAX) issued fourth-quarter earnings view below market estimates, and trimmed fiscal 2022 outlo…


Source:Finanz Nachrichten
Baxter International Inc. 2022 Q3 - Results - Earnings Call Presentation
Oct 27, 2022 12:13pm

The following slide deck was published by Baxter International Inc.


Source:Seeking Alpha
Baxter reduces full-year adjusted EPS outlook range to below consensus
Oct 27, 2022 12:04pm

Baxter International (BAX) has amended its full-year 2022 adjusted EPS guidance to $3.53-$3.60 from a prior outlook of $3.60-$3.70, falling below the Street consensus of $3.62.


Source:Seeking Alpha
Baxter International Inc. Q3 Earnings Summary
Oct 27, 2022 11:52am

DEERFIELD (dpa-AFX) - Below are the earnings highlights for Baxter International Inc. (BAX):Earnings: -$2.94 billion in Q3 vs. $450 million in the same period last year. EPS: -$5.83 in Q3 vs. $0.9…


Source:Finanz Nachrichten
Baxter Non-GAAP EPS of $0.82 in-line, revenue of $3.8B beats by $30M (NYSE:BAX)
Oct 27, 2022 11:18am

Baxter press release (BAX): Q3 Non-GAAP EPS of $0.82 in-line.Revenue of $3.8B (+17.6% Y/Y) beats by $30M.Sales in the U.S. totaled $1.8 billion, increasing 40% on a reported basis…


Source:Seeking Alpha
Baxter Q3 2022 Earnings Preview
Oct 26, 2022 15:47pm

Baxter (BAX) is scheduled to announce Q3 earnings results on Thursday, October 27th, before market open.The consensus EPS Estimate is $0.82 (-19.6% Y/Y) and the consensus Revenue Estimate…


Source:Seeking Alpha
Baxter International Inc. – Consensus Indicates Potential 21.3% Upside
Oct 24, 2022 11:08am

Baxter International Inc. with ticker code (BAX) now have 14 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 77 and 60 with the average target price sitting at 66.71. With the stocks previous close at 55 this now indicates there is a potential upside of 21.3%. The 50 day MA is 57.27 and the 200 moving average now moves to 70.58. The market capitalisation for the company is $28,419m. Find out more information at: https://www.baxter.com [stock_market_widget type="chart" template="basic" color="green" assets="BAX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $34,469m based on the market concensus. Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.


Source:DirectorsTalk
Baxter International: Shares Still Expensive, Bearish Momentum Into Earnings (NYSE:BAX)
Oct 24, 2022 10:21am

Baxter has an unattractive valuation, a bearish trend, and poor earnings history in terms of stock price reactions. Click here to see why BAX is a sell.


Source:Seeking Alpha
Baxter International Stock: Attractive Despite Weakening Bottom Line
Oct 24, 2022 02:01am

Baxter International has had a rough year or so, with shares declining far more than the market has. See why I''m changing my rating on BAX from Hold to a Buy.


Source:Seeking Alpha
Garrison Asset Management, LLC Buys 1, Sells 4 in 3rd Quarter
Oct 21, 2022 19:00pm

Related Stocks: SNY , BAX , VZ , MRK , SCHB ,


Source:GuruFocus
Patient Centric Healthcare App Global Market Report 2022: Enhanced Access and Flexibility with Novel Technologies Driving Growth - ResearchAndMarkets.com
Oct 20, 2022 08:30am


Source:Kwhen Finance
US drug maker Baxter opens R&D centre in Ahmedabad
Oct 18, 2022 06:54am

Baxter said the Ahmedabad R&D centre will help the company to accelerate innovation in generic and differentiated injectable pharmaceuticals.


Source:Economic Times India
Baxter inaugurates global pharma R&D centre in Ahmedabad
Oct 18, 2022 06:52am

The centre will help further the company''s mission of saving and sustaining lives by accelerating innovation in the generic and differentiated injectable pharma space The post Baxter inaugurates global pharma R&D centre in Ahmedabad appeared first on Express Pharma .


Source:Express Pharma
Have you been able to find a good deal on Baxter International Inc.’s shares?
Oct 07, 2022 14:32pm

Baxter International Inc. (NYSE:BAX) closed Thursday at $56.25 per share, down from $57.71 a day earlier. While Baxter International Inc. has underperformed by -2.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BAX fell by -30.44%, with highs and lows ranging from $89.70 to $53.78, whereas […]


Source:US Post News
Blood Clotting Factors Market Expected to Expand at a Steady 2022-2028 | Shire Plc, Baxter International Inc., Grifols International SA, Roche AG
Oct 04, 2022 12:39pm

Coherent Market Insights has released a new research study on the "Blood Clotting Factors Market" which aims to provide a thorough examination of the factors influencing global business introduction and outlook. The Global Blood Clotting Factors Market Report detailed information


Source:OpenPR